Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5063713 | 0.97 | HSP90AA1 (0.38) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL28789193 | 0.78 | TSHR (0.35) | HSP90AA1TSHRALDH1A1 | |
| SCHEMBL10176540 | 0.77 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL688290 | 0.77 | HSP90AA1 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL6397176 | 0.71 | HSP90AA1 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL4968872 | 0.71 | CA2 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL306807 | 0.71 | TSHR (0.41) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL3140190 | 0.71 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL7633171 | 0.71 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL7096547 | 0.70 | ALDH1A1 (0.36) | HSP90AA1CA2CA4CA5ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0139731-A1 | 5-ETHYNYL-PROSTACYCLYNE, PRODUCTION PROCESS THEREOF AND PHARMACEUTICAL UTILISATION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-05-08 | — | — | EP | claimed |
| WO-1984004307-A1 | 5-ETHYNYL-PROSTACYCLYNE, PRODUCTION PROCESS THEREOF AND PHARMACEUTICAL UTILISATION THEREOF | SCHERING AG (DE) | 1984-11-08 | — | — | WO | claimed |
| US-20120074336-A1 | LIGHT-DRIVEN ROTARY MOLECULAR MOTORS | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE (US) | 2012-03-29 | — | — | US | disclosed |
| US-7964722-B2 | Light-driven rotary molecular motors | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1735303-B1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077394-A1 | LIGHT-DRIVEN ROTARY MOLECULAR MOTORS | NATIONAL SCIENCE FOUNDATION | 2011-03-31 | — | — | US | disclosed |
| US-7872032-B2 | 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PARMACEUTICALS INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7638539-B2 | 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1735303-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097763-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097762-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-0879814-B1 | Triaromatic compounds, compositions containing them and uses thereof | CT INTERNAT DE BR RECH S DERMA (FR) | 2001-11-28 | — | — | EP | disclosed |
| EP-0879814-A1 | Triaromatic compounds, compositions containing them and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-11-25 | — | — | EP | disclosed |
| EP-0139731-A1 | 5-ETHYNYL-PROSTACYCLYNE, PRODUCTION PROCESS THEREOF AND PHARMACEUTICAL UTILISATION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-05-08 | — | — | EP | disclosed |
| WO-1984004307-A1 | 5-ETHYNYL-PROSTACYCLYNE, PRODUCTION PROCESS THEREOF AND PHARMACEUTICAL UTILISATION THEREOF | SCHERING AG (DE) | 1984-11-08 | — | — | WO | disclosed |
| US-4065620-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4052421-A | 13-ETHINYL-STEROIDS AND PROCESSES FOR THEIR MANUFACTURE | CIBA-GEIGY CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275621-A1 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | PPARD, PPARA, PPARG | HSP90AA1 2731/4885CA2 3754/4885CA4 4341/4885 |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | HSP90AA1 963/4885CA2 4547/4885CA4 4848/4885 |
| US-20110077394-A1 | LIGHT-DRIVEN ROTARY MOLECULAR MOTORS | CCNA2, CCNO, SCO2 | HSP90AA1 4079/4885CA2 642/4885CA4 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.